Lung Caner study 1:

Study name:

A Randomized, Placebo-controlled, double-blind, multi-center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Eligibility:

Participants with locally advanced NSCLC with KRAS G12C mutation.

Treatment 1:

Platinum-based chemotherapy + zipalertinib

Treatment 2:

Platinum-based chemotherapy

Lung Caner study 2:

Study name:

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation

Eligibility:

Patients with previously untreated, unresectable, locally advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 >=50%

Treatment 1:

Adagrasib + Pembrolizumab

Treatment 2:

Pembrolizumab alone

Lung Caner study 3:

Study name:

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Eligibility:

Stage IB-IIIA NSCLC, no prior (neo) adjuvant chemotherapy

Treatment 1:

Zipalertinib + Chemotherapy (4 cycles) followed by zipalertinib (total of 3 years)

Treatment 2:

Placebo + Chemotherapy (4 cycles) followed by placebo (total of 3 years)

NOTE: Chemotherapy will include cisplatin or carboplatin plus pemetrexed